HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[DNA ploidy is an independent prognostic biomarker in breast invasive ductal carcinoma].

AbstractOBJECTIVE:
To evaluate 'classic' prognostic parameters, as well as DNA ploidy and S-phase fraction, in relation to disease-free and overall survival in breast invasive ductal carcinoma with long-term follow-up.
MATERIAL AND METHODS:
The study involved 400 patients with breast invasive ductal carcinoma and median follow-up of 134 months (50-240). Histological grading, tumour size, axillary nodal involvement, pathological staging and hormone-receptor status were assessed as established prognostic markers. Ploidy and S-phase fraction were determined prospectively by DNA flow cytometry using fresh/frozen tissue. A Cox regression model was used for statistical analysis of the prognostic variables.
RESULTS:
There were 106 deaths (26.5%) and 141 disease recurrences (35.2%) during follow-up. Two hundred thirty-five (58.7%) tumours were aneuploid. High S-phase fraction and aneuploidy were associated with tumours with higher grade of differentiation, greater size and negative hormonal receptors. In univariate analysis, all the clinicopathological and cytometric features (including patients < 40 years and a subgroup presenting hipertetraploid/multiploid tumours), but S-phase fraction and estrogen receptors for disease free survival, significantly correlated with clinical outcome. In multivariate analysis, advanced disease stage, DNA aneuploidy and lack of progesterone receptors retained statistically significant association with shorter survival. In the subgroup of patients with intermediate differentiation tumours (G2), aneuploidy associated with worse prognosis. In the subset of node-negative patients, only estrogen receptors showed significant correlation with disease evolution. In node-positive patients, greater size tumours and aneuploidy (in relation to overall survival) were indicators of worse prognosis.
CONCLUSION:
Along with disease staging and hormone-receptor expression, DNA ploidy is an independent prognostic biomarker of long-term survival in breast invasive ductal carcinoma.
AuthorsAntónio E Pinto, Teresa Pereira, Giovani L Silva, Mónica C Ferreira, Saudade André
JournalActa medica portuguesa (Acta Med Port) 2012 Nov-Dec Vol. 25 Issue 6 Pg. 399-407 ISSN: 1646-0758 [Electronic] Portugal
Vernacular TitleA ploidia de ADN é um biomarcador prognóstico independente no carcinoma ductal invasivo da mama.
PMID23534591 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Genetic Markers
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms (genetics, mortality)
  • Carcinoma, Ductal, Breast (genetics, mortality)
  • Female
  • Genetic Markers
  • Humans
  • Middle Aged
  • Ploidies
  • Prognosis
  • Prospective Studies
  • Survival Rate
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: